Glucagon‐like peptide 1 receptor agonists (GLP‐1 RAs) have proven beneficial in type 2 diabetes, are amongst the few medicines approved for weight management, and are also licensed for focused cardiovascular risk reduction. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.